MiMedx Group (NASDAQ:MDXG) Releases Earnings Results, Beats Expectations By $0.05 EPS

MiMedx Group (NASDAQ:MDXG) posted its quarterly earnings data on Wednesday. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05, FiscalAI reports. The firm had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.

Here are the key takeaways from MiMedx Group’s conference call:

• MiMedx reported record 2025 results — full‑year net sales of $419M (+20%), Q4 net sales of $118M (+27%), adjusted EBITDA ~$106M and a net cash balance near $148M, strengthening profitability and liquidity.
• The Medicare reimbursement reset (price cap ~$127/cm²) and WISeR prior‑auth implementation have caused near‑term disruption, lower ASPs and slower wound volumes; management guides 2026 revenue of $340–360M with adjusted EBITDA in the mid‑to‑high teens.
• The surgical franchise is a clear growth driver — surgical sales grew ~25% in Q4 and 20% for the year, supported by increased commercial resources, new launches like AMNIOFIX Thyroid Shield, and recently licensed complementary surgical products.
• Strong capital flexibility: the company holds substantial cash and the board authorized a $100M share repurchase program over two years while remaining open to disciplined M&A to accelerate strategy.
• Clinical evidence push: the EPIEFFECT randomized controlled trial is nearly fully enrolled with results and publications expected soon, and an RCT for CHORIOFIX is planned, reinforcing the company’s evidence‑based positioning.

MiMedx Group Trading Down 1.3%

Shares of MDXG traded down $0.07 during midday trading on Wednesday, hitting $5.28. The stock had a trading volume of 739,895 shares, compared to its average volume of 808,538. MiMedx Group has a 1 year low of $4.89 and a 1 year high of $8.46. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The stock’s 50 day moving average is $5.82 and its 200 day moving average is $6.61. The firm has a market cap of $781.97 million, a PE ratio of 14.08 and a beta of 1.59.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Mizuho reduced their price target on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Lake Street Capital lowered their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. UBS Group set a $10.00 price objective on shares of MiMedx Group in a research report on Monday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.60.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds have recently bought and sold shares of the business. Royal Bank of Canada grew its position in shares of MiMedx Group by 1.4% during the 1st quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after buying an additional 13,629 shares in the last quarter. AQR Capital Management LLC increased its position in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after purchasing an additional 4,296 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of MiMedx Group in the 1st quarter valued at about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after purchasing an additional 4,049 shares during the period. Finally, Millennium Management LLC lifted its position in shares of MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after purchasing an additional 596,016 shares during the period. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.